CF 301

Drug Profile

CF 301

Alternative Names: CF-301

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Rockefeller University
  • Developer ContraFect
  • Class Antibacterials; Enzymes
  • Mechanism of Action Cell membrane inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacteraemia
  • Preclinical Staphylococcal infections
  • No development reported Skin and soft tissue infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections in USA
  • 29 Mar 2016 Adverse events and pharmacokinetics data from a phase I trial for Bacteraemia (In volunteers) released by ContraFect
  • 15 Dec 2015 Adverse events data from a phase I trial in Bacteraemia released by ContraFect
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top